TXNIP and metabolic syndrome: The outcome reveals, for the first time, a link of target pharmacology to insulin resistance, dysglycemia, blood pressure, dyslipidemia, and low-grade inflammation—including key mediators of insulin resistance, TXNIP, and TNFα.